Key Highlights

  • Vectus Biosystems (ASX:VBS) closed at $0.05 on 12 November 2026, down 16.67% over the session.
  • The FDA granted the company's request for a pre-IND Type B meeting on its VB0004 programme in idiopathic pulmonary fibrosis.
  • FDA written responses are expected by mid-November 2026, according to the company's Quarterly Report dated 29 October 2026.

Vectus Biosystems Limited (ASX:VBS) shares closed at $0.05 on 12 November 2026, a fall of 16.67% over the trading session, while the S&P/ASX 200 closed at 9,146.80, down about 6.40 points or roughly 0.07%. Vectus is a clinical-stage biotechnology company developing VB0004, a first-in-class oral compound for idiopathic pulmonary fibrosis. The latest update is its quarterly activities report and Appendix 4C, dated 29 October 2026, which covered the regulatory pathway for VB0004 in the United States.

FDA Pre-IND Meeting for VB0004

Vectus said the US Food and Drug Administration had granted its request for a pre-IND Type B meeting covering the proposed development programme for VB0004 in idiopathic pulmonary fibrosis. The interaction will take the form of written responses from the FDA, which are expected by mid-November 2026. The company and its US regulatory agent, Cardinal Health Regulatory Services, began preparing the meeting package for submission.

Development Stage and Regulatory Support

Vectus has completed a Phase Ia study in healthy volunteers, which the company said established a favourable safety and pharmacokinetic profile. The pre-IND feedback is intended to guide the next stages of clinical and regulatory development, and the company describes idiopathic pulmonary fibrosis as a progressive and often fatal disease with significant unmet need.

Sector Context

Vectus operates in the early clinical biotech segment, where progress is measured by regulatory feedback, trial design and funding. Companies at this stage typically rely on Capital Markets and partnering to advance programmes, and share prices can react to regulatory milestones. The S&P/ASX 200 was little changed on 12 November, so the fall in Vectus shares was company-specific.

Risks and Limitations

The FDA feedback is still pending, and the company has not yet started a Phase II or later trial. Early-stage Drug Development carries high attrition risk, and a favourable safety profile in healthy volunteers does not guarantee results in patients with pulmonary fibrosis. Further funding will likely be needed to advance the programme.

What to Watch Ahead

Investors will be watching for the FDA's written responses, expected by mid-November, and for the company's plan for the next clinical and regulatory steps. Any update on the funding required to progress VB0004 will also be followed.

Final Word

Vectus has taken a regulatory step with the FDA on its lead programme, and the written responses will show what the agency expects next. The share price fall on 12 November came without a new announcement from the company on the day.